Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)

被引：7
|
作者：
George, D. J. [1 ]
Michaelson, M. D. [2 ]
Rosenberg, J. E. [3 ]
Redman, B. G. [4 ]
Hudes, G. R. [5 ]
Bukowski, R. M. [6 ]
Kim, S. T. [7 ]
Chen, I.
Wilding, G. [8 ]
Motzer, R. J. [9 ]
机构：
[1] Duke Univ, Ctr Med, Durham, NC 27706 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Philadelphia, PA USA
[6] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[7] Pfizer Inc, La Jolla, CA USA
[8] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA
[9] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71148-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4517
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [21] Sunitinib in patients with metastatic renal cell carcinoma
    Motzer, Robert J.
    Rini, Brian I.
    Bukowski, Ronald M.
    Curti, Brendan D.
    George, Daniel J.
    Hudes, Gary R.
    Redman, Bruce G.
    Margolin, Kim A.
    Merchan, Jaime R.
    Wilding, George
    Ginsberg, Michelle S.
    Bacik, Jennifer
    Kim, Sindy T.
    Baum, Charles M.
    Michaelson, M. Dror
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2516 - 2524
  • [22] A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).
    Hutson, T. E.
    Bukowski, R. M.
    Rini, B. I.
    Gore, M. E.
    Larkin, J. M. G.
    Figlin, R. A.
    Barrios, C. H.
    Escudier, B.
    Lin, X.
    Fly, K. D.
    Martell, B.
    Matczak, E.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling
    Thodima, V. J.
    Molina, A. M.
    Jia, X.
    Zhang, J.
    Georges, M. E.
    Patil, S.
    Reuter, V. E.
    Motzer, R. J.
    Chaganti, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Outcomes of sunitinib therapy in patients (pts) with metastatic renal cell carcinoma (mRCC) with poor risk features
    Barroso-Sousa, Romualdo
    Munhoz, Rodrigo Ramella
    Fonseca, Leonardo Gomes
    de Sousa Fede, Angelo Bezerra
    Marques Linck, Rudinei Diogo
    Venchiarutti Moniz, Camila Motta
    Mak, Milena Perez
    Souza, Ciro Eduardo
    Hoff, Paulo M.
    Dzik, Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [25] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Predictive biomarkers in metastatic Renal Cell Carcinoma (mRCC) patients treated with neoadjuvant sunitinib (PREINSUT trial)
    Mauge, L.
    Pereira, H.
    Gille, A. S.
    Bouaboula, M.
    Grine, A.
    Elaidi, R. T.
    Tartour, E.
    Fournier, L.
    Oudard, S.
    Helley, D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S34 - S34
  • [27] Smoking habit and its impact on the efficacy and safety of sunitinib in metastatic renal cell carcinoma (mRCC) patients
    Ruiz, A. L.
    Suarez, B.
    Llinares, J.
    Esteban, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S656 - S657
  • [28] Hypertension and myelosuppression as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC)
    Qin, Shukui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Jian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [29] Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Feldman, D. R.
    Kondagunta, G. V.
    Ronnen, E. A.
    Fischer, P.
    Chang, R.
    Baum, M.
    Ginsberg, M. S.
    Ishill, N.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Neutropenia and Thrombocytopenia During Treatment as Biomarkers of Sunitinib Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)
    Donskov, F.
    Carus, A.
    Barrios, C. H.
    Escudier, B.
    Li, S.
    Perkins, J.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S136 - S136
12345